PTT invests 1.04 billion to send “Inobic” to hold Inter Pharma extending health products

PTT invests 1.04 billion to send “Inobic” to hold Inter Pharma extending health products

Date 21 May 2022 at 10:30 a.m.

PTT Board gave the green light to buy 20% of Inter Pharma’s shares worth 1,043 million baht to support ‘Innobic’ moving forward in a comprehensive health business. Expanding covering market channels throughout the country

Mr. Attaphol Rerkpiboon, Chief Executive Officer and President of PTT Public Company Limited revealed that the Board of Directors of PTT at the meeting No. 5/22 had a resolution to approve Innobic L. L Holding Co., Ltd., which is wholly owned by Inobic (Asia) Co., Ltd. (Inobic) (a subsidiary of PTT), purchased the newly issued ordinary shares of Inter Pharma Public Company Limited. ) or IP offered for sale to a private placement (Private Placement) accounted for 20% of the registered and paid-up capital This investment has a total value of approximately 1,043 million baht.

The investment contract is expected to be signed by June 2022 and trading will be completed in 3Q22, subject to the approval of the Securities and Exchange Commission. and the Extraordinary General Meeting of Shareholders of IP

This collaboration will help build on the research and development of a full range of health products ranging from innovative medicine, eye healthcare, to nutraceuticals and dietary supplements. (Nutraceuticals & Supplements), Thai Herbal Medicines, Health Food and Drink and expanding the market to cover all over Thailand.

Inter Pharma (IP) Company Limited informed the Stock Exchange of Thailand on May 20 that the Board of Directors No. 4/22 on May 19, 2022 approved to propose to the shareholders’ meeting to consider and approve the Increase the registered capital of the company 57,602,430.50 baht from the original registered capital of 158,616,195 baht. 16,218,625.50 baht by issuing 115,204,861 newly issued ordinary shares with a par value of 0.50 baht per share to be allocated to a private placement of 74,510,000 shares, reserved for the adjustment of the rights of the warrants to purchase 1,854,902 ordinary shares of the Company No. 1 (IP-W1) and a reserve for a general mandate of 38,839,959 shares.

In this regard, it was resolved to propose to the shareholders’ meeting to consider and approve the allocation of 74,510,000 newly issued ordinary shares at the offering price of 14 baht per share, representing a total value. 1,043,140,000 baht to be offered to INNOBIC LL, which is a private placement (PP). The proceeds from the capital increase will be used. Expand business to businesses related to the company’s current business related to health, such as hospitals, wholesale drugstores, herbal factories. Tele-pharmacy Telemedicine, etc., about 500 million baht, which the project is in the study. including contacting in the acquisition All projects should generate income for the company at least 1,000-1,500 million baht per year.

There is also an investment in the EU standard project of eye drug production of the company’s factory in Ayutthaya, about 100 million baht, which is a project in the process of being studied. The whole project should generate income for the company at least 100 million baht per year, including creating a department for the production of cosmetics and effervescent tablets of the Modern Pharma factory about 50 million baht. should generate income for the company at least 75 million baht per year

At the same time, there is a plan to expand a pharmacy branch about 100 million baht. The whole project should generate income for the company at least 150 million baht per year, including bringing the money to repay the loan of about 150 million baht and use it for The working capital is 100 million baht.

<!–

–>

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.